Posted inNews PrEP Prevention Research
Twice-yearly lenacapavir 89% more effective than Truvada
New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inInternational News PrEP Prevention
Concern as PrEP supplies run low in Australia
Australian sexual health and HIV organisations are sending out reminders for PrEP users to "plan…
Posted inHealthcare International News PrEP Prevention
PrEP approved to prevent HIV in Japan
Japan has approved the use of Truvada (TDF/FTC), sold by Gilead Sciences under the brand name Truvada, as PrEP for the prevention of HIV in the country.